AD	

Award Number: W81XWH-06-0171

TITLE: Androgen, Estrogen, and the Bone Marrow Microenvironment

PRINCIPAL INVESTIGATOR: Beatrice Knudsen, M.D., Ph.D.

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center

Seattle, WA 98109-1024

REPORT DATE: December 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Form Approved REPORT DOCUMENTATION PAGE OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE 2. REPORT TYPE 3. DATES COVERED 28-12-2007 29 NOV 2006 - 28 NOV 2007 Annual 4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER Androgen, Estrogen, and the Bone Marrow Microenvironment **5b. GRANT NUMBER** W81XWH-06-0171 **5c. PROGRAM ELEMENT NUMBER** 6. AUTHOR(S) 5d. PROJECT NUMBER Beatrice Knudsen, M.D., Ph.D. 5e. TASK NUMBER 5f. WORK UNIT NUMBER Email: bknudsen@fhcrc.org 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Fred Hutchinson Cancer Research Center Seattle, WA 98109-1024 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT In this project we plan to analyze androgen- and estrogen-responsive gene expression in the bone marrow. We plan to work to: determine if castration-induced gene expression changes in mouse bone marrow are caused by the deficiency of testosterone or estrogen; analyze androgen- and estrogen-sensitive cytokine and gene expression changes in human bone marrow transplanted into NOD/SCID mice, and; examine androgen- and estrogen-sensitive gene expression in the bone marrow of patients with low and high circulating testosterone levels. Preliminary results show that with the androgen metabolizing genes examined in the bone marrow samples from patients with prostate cancer there is little evidence for a positive correlation between androgen (testosterone) and androgen metabolizing gene expression levels. 15. SUBJECT TERMS Bone marrow metastasis, androgen, animal model, patient outcome 16. SECURITY CLASSIFICATION OF: 17. LIMITATION 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON **OF ABSTRACT OF PAGES USAMRMC**

UU

a. REPORT

U

b. ABSTRACT

U

c. THIS PAGE

19b. TELEPHONE NUMBER (include area

code)

6

Table of Contents

	Page
Introduction	4
Body	4
Key Research Accomplishments	4
Reportable Outcomes	5
Conclusions	5
References	6
Appendices	N/A

"Androgen, Estrogen, and the Bone Marrow Microenvironment"

INTRODUCTION:

In this project we plan to analyze androgen- and estrogen-responsive gene expression in the bone marrow. We postulate that gene and protein expression in the bone marrow microenvironment is subject to regulation by androgen and estrogen and could affect the growth and progression of micrometastatic prostate cancer cells. When prostate cancer cells leave the circulation through fenestrations in the bone vasculature, they lodge in the fertile soil of the bone marrow. Interactions between prostate cancer cells and the bone marrow regulate the early steps of metastasis formation. This environment differs from the environment of established prostate cancer metastasis, in which a fibrotic bone marrow stroma surrounds the cancer cells and cancer cells stimulate an osteoblastic response in adjacent bone. Almost nothing is known about the initial interactions of micrometastatic prostate cancer with the bone marrow microenvironment (BM-ME). During this period critical decisions in the fate of micrometastatic cancer cells occur that determine their latency, survival and proliferation. Most likely, factors in the BM-ME play a major role in regulating the progression of micrometastatic disease. While model systems exist for several steps in metastasis formation, including interactions of prostate cancer cells with endothelial cells and osteoblastic and osteoclastic bone cells, there is no *in-vivo* system to investigate the interactions between prostate cancer cells and the BM-ME. Therefore, there are many unanswered questions related to events that will ultimately determine who develops lethal prostate cancer metastases. In this grant application we will begin to investigate mechanisms that control the fate of prostate cancer cells when they first enter the BM.

Early androgen ablation has a significant survival benefit in patients at risk for prostate cancer recurrence or with increasing PSA levels after surgery or radiation therapy. At the initiation of androgen ablative therapy, the disease is often not apparent by conventional radiographic methods. However, the majority of patients will have micrometastatic disease outside the prostate. Therefore it is important to understand if and how androgen ablative therapy affects the bone marrow cells that surround the micrometastatic cancer cells. In this study, we plan to work to: determine if castration-induced gene expression changes in mouse bone marrow are caused by the deficiency of testosterone or estrogen; analyze androgen- and estrogen-sensitive cytokine and gene expression changes in human bone marrow transplanted into NOD/SCID mice, and; examine androgen- and estrogen-sensitive gene expression in the bone marrow of patients with low and high circulating testosterone levels.

BODY:

This research project was subject to second-level review by the U.S. Army Medical Research Material Command's Human Subjects Research Review Board (HSRRB). Because of this review, study implementation was precluded until we met specific requirements for compliance with human subjects protection and received approval from our local IRB and then the HSRRB. We received final approval from the HSRRB on November 21, 2006.

KEY RESEARCH ACCOMPLISHMENTS:

- 1) We have obtained human samples of bone marrow from twenty patients with prostate cancer which we have analyzed for testosterone levels.
- 2) Gene expression has been analyzed for six androgen sensitive genes in four of the twenty bone marrow samples. (androgen sensitive genes: AKR1C1, AKR1C2, AKR1C3, RODH-4, RODH-5, and RL-HSD)
- 3) We have obtained CD45+ samples from which we are currently analyzing changes in gene expression for androgen sensitive genes.
- 4) We are organizing the animal work for the human bone marrow xenograft studies in mice.

REPORTABLE OUTCOMES:

A) Testosterone levels for twenty samples from bone marrow of patients with prostate cancer have been analyzed and subdivided into the top and bottom quartiles. (see table)

Table 1. Testosterone levels in patients with prostate cancer

BM T - ng/ml	Tab	ie 1. Testosterone ie	veis in patients wi
1 23316K 0.2 2 23343R 0.56 3 23334D 0.68 4 23290M 0.69 5 23289C 0.72 6 23333L 0.82 7 23349C 0.82 8 23283K 1.03 9 23329L 1.03 10 23331K 1.03 11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66			BM
2 23343R 0.56 3 23334D 0.68 4 23290M 0.69 5 23289C 0.72 6 23333L 0.82 7 23349C 0.82 8 23283K 1.03 9 23329L 1.03 10 23331K 1.03 11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66		sample i.d.	T - ng/ml
2 23343R 0.56 3 23334D 0.68 4 23290M 0.69 5 23289C 0.72 6 23333L 0.82 7 23349C 0.82 8 23283K 1.03 9 23329L 1.03 10 23331K 1.03 11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66			
2 23343R 0.56 3 23334D 0.68 4 23290M 0.69 5 23289C 0.72 6 23333L 0.82 7 23349C 0.82 8 23283K 1.03 9 23329L 1.03 10 23331K 1.03 11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66			
3 23334D 0.68 4 23290M 0.69 5 23289C 0.72 6 23333L 0.82 7 23349C 0.82 8 23283K 1.03 9 23329L 1.03 10 23331K 1.03 11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	1	23316K	0.2
4 23290M 0.69 5 23289C 0.72 6 23333L 0.82 7 23349C 0.82 8 23283K 1.03 9 23329L 1.03 10 23331K 1.03 11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	2	23343R	0.56
5 23289C 0.72 6 23333L 0.82 7 23349C 0.82 8 23283K 1.03 9 23329L 1.03 10 23331K 1.03 11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	3	23334D	0.68
6 23333L 0.82 7 23349C 0.82 8 23283K 1.03 9 23329L 1.03 10 23331K 1.03 11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	4	23290M	0.69
7 23349C 0.82 8 23283K 1.03 9 23329L 1.03 10 23331K 1.03 11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	5	23289C	0.72
8 23283K 1.03 9 23329L 1.03 10 23331K 1.03 11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	6	23333L	0.82
9 23329L 1.03 10 23331K 1.03 11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	7	23349C	0.82
10 23331K 1.03 11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	8	23283K	1.03
11 23319B 1.08 12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	9	23329L	1.03
12 23300B 1.14 13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	10	23331K	1.03
13 23340K 1.25 14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	11	23319B	1.08
14 23301H 1.26 15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	12	23300B	1.14
15 23285C 1.28 16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	13	23340K	1.25
16 23253G 1.31 17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	14	23301H	1.26
17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	15	23285C	1.28
17 23293M 1.4 18 23291C 1.41 19 23320H 1.66	16	23253G	1.31
18 23291C 1.41 19 23320H 1.66	17	23293M	
 			1.41
 	19	23320Н	1.66
1.74	20	23328J	1.94

Top and	bottom	quartiles	from
Table 1			

Bone Marrow		BM	
Testo	Testosterone levels		
1	23316K	0.2	
2	23343R	0.56	
3	23334D	0.68	
4	23290M	0.69	
5	23289C	0.72	
6	23253G	1.31	
7	23293M	1.4	
8	23291C	1.41	
9	23320H	1.66	
10	23328J	1.94	
	_		
low Testosterone Levels			
High Testosterone Levels			

B) Two bone marrow samples were selected from the top and bottom quartiles for evaluation of five androgen metabolising genes (Table 2).

Table 2. Bone Marrow gene expression levels for selected androgen metabolising genes

	-: 8					9 8
Bones Marrow Sample	Testosterone (ng/ml)	AKR1C1	AKR1C2	AKR1C3	RL-HSD	RODH-4
23334D	0.680	0.160	0.062	3.204	0.002	0.006
23343R	0.560	10.056	0.010	0.505	0.026	0.002
23328J	1.940	0.003	0.004	0.039	0.002	0.018
23253G	1.310	7.499	0.317	0.201	0.005	0.034
PEC control	n/a	0.027	0.054	0.867	0.000	0.000

All gene expression values are de-logged Ct's normalized to ACTB

low	high	
testosterone	testosterone	

CONCLUSIONS:

Preliminary results show that with the androgen metabolizing genes examined in the bone marrow samples from patients with prostate cancer there is little evidence for a positive correlation between androgen (testosterone) and androgen metabolizing gene expression levels. It is expected that testing the remaining six

B. Knudsen, Annual Report, Page 6

samples in the two quartiles will either verify the lack of a relationship between androgen and androgen metabolising gene expression in metastatic prostate cancer of the bone marrow of these samples or reveal a technical problem with the analysis.

REFERENCES:

None